GoodRx Holdings Inc at JPMorgan Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : Scott, I really wanted to start by just getting your insights. I know you and I had a conversation at your Analyst Day of what you were looking for in a permanent CEO. So maybe if you could spend a minute talking about what you found in Wendy?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : Thank you, Scott, so much for those comments. We are in an Investor Conference, and I did forget to ask Karsten to please read the safe harbor statement. So we're going to read that first, and then we'll get into the Q&A.

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : Great. Thanks very much. And Scott, thanks for all those insights into how you were thinking about selecting the right person. Wendy, from your perspective, when you were thinking about taking this job, what really drew you to GoodRx?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : What would you say are the key priorities for you in your first year?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : Is there anything that you would characterize as an easy win in the early days rather than thinking about longer-term priorities?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : I want to dig in a little deeper on the pharma manufacturing solutions side of your business. You talked about the growth that you've seen there. You talked about some of the early discussions. But can you maybe talk about the benefit you think that GoodRx can bring to the whole ecosystem? And really, when you're talking to those manufacturers, what are you talking to them about? What the offerings are from your perspective?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : Wendy, I think it'd be really helpful for people in the audience to really understand, maybe if you can give us an example of exactly how this would work, whether it's the co-pay assistance, the point of sale, et cetera? So maybe just walk us through, even when you just have a made-up drug, it's fine.

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : When we think about this business, you've talked about the exceptional growth over the last few years. How do you think about this business going forward? And how big a piece of the business do you think it will be over time?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : Yes, just the manufacturer. Yes.

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : High deductible health plans have been around for some time. But when we think about that continued growth in high deductible health plans. For many of you, you probably know this, but just to remind you. For high deductable health plans, it's both pharmacy and medical together. So

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : Is there anything else on the plan design side, Wendy, that you see changing that could have an impact to GoodRx?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : When we think about the actual prescription that comes from the provider, where are you investing in those relationships with the provider? And is it just simply education. Again, there's a difference in what they prescribe, right, and really starts at that point? And are they understanding what

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : It's a very challenging time for retailers, especially drug retailers. Can you talk about their interest in partnership and working together with GoodRx as they work through some of their challenges?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : So when I think about those cost plus models that you talked about, is there any difference in the economics to your model for cost plus?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : When the PBMs does not contract with you currently for price transparency for your transparency tool, how do you view the landscape of price transparency tools and are there differentiated value propositions? Is there a way to convince these not to build them themselves? Like what's the value of build it yourself or work with GoodRx?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : You have recognition, right? I mean I think your name is much --

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : I want to talk about retail closures. So you -- prior to your time, Wendy, with the company, that there was a revenue headwind due to some store closures. Companies like Walgreens have talked about closing 1,200 stores. CVS has closed over 900 stores. As you know, Rite Aid had to close nearly half of their stores. As we think about that on a go-forward basis, you, Karsten, can you talk about the future? What you see here? What the impact it could potentially have to volumes as we think about those continued store closings?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : Looking back on '24, ISP volumes ramping throughout the year. You talked about your expectations. We talked a lot about it at the Analyst Day. Can you maybe just talk about longer-term targets and what you've been seeing in that product line?

Question: Lisa Gill - J.P. Morgan Securities LLC - Analyst : Wendy, this is our last minute here. The stock has been under a lot of pressure. When we're sitting together here next year, what do you hope that investors will appreciate about, not just the company, but also about the stock over the next 12 months?